Amendment Dated: February 6, 2007

Reply to Office Action Dated: September 6, 2006

AMENDMENT TO THE CLAIMS

Please amend the claims as follows:

Claims 1-12 (Cancelled).

Claim 13 (Currently amended). A method for the treatment of a pathology

affecting internal tissues of an eye, comprising identifying a subject in need of

treatment of a pathology affecting internal tissues of an eye, topically applying

the administration of a composition comprising from 10 to 500 µg/ml of nerve

growth factor over an ocular surface of the a subject in need thereof, wherein

said nerve growth factor passes through external tissues of said eye to said

internal tissues and wherein said internal tissues of the eye are selected from the

group consisting of sclera, ciliary bodies, crystalline lens, retina, vitreous body,

and choroidea, and treating the pathology affecting the internal tissues of the eye

of the subject in need thereof.

Claim 14 (Previously presented). The method of claim 13, wherein the

composition comprises the nerve growth factor in a pharmaceutically acceptable

ophthalmic carrier and is in a form selected from the group consisting of

solutions, suspensions, ointments, gels, or creams.

Claim 15 (Previously presented). The method of claim 13, wherein the

composition is in a form selected from the group consisting of an ocular erodible

insert, a polymeric membrane reservoir system to be placed in the conjunctival-

sac, or in combination with a local bandage and a therapeutic contact lens.

Claim 16 (Cancelled).

3

Amendment Dated: February 6, 2007

Reply to Office Action Dated: September 6, 2006

Claim 17 (Currently amended). The method of claim <u>13</u> <del>16</del>, wherein the pathology has a trophic, post-traumatic, infective, post-surgical, autoimmune, dystrophic, or degenerative origin, or is originated by laser treatment.

Claim 18 (Previously presented). The method of claim 14, wherein the composition is in the form of an ophthalmic solution.

Claim 19 (Previously presented). The method of claim 18, wherein the ophthalmic solution contains from 200-250 µg/ml of nerve growth factor.

Claim 20 (Previously presented). The method according to claim 13, wherein the nerve growth factor is of murine or human origin, or is a human recombinant nerve growth factor.

Claim 21 (Currently amended). A method for the treatment of a pathology affecting internal tissues of an eye, comprising identifying a subject in need of treatment of a pathology affecting internal tissues of an eye, topically applying the administration of a composition comprising nerve growth factor over an ocular surface of the a subject in need thereof, wherein said nerve growth factor passes through external tissues of said eye to said internal tissues and wherein said internal tissues of the eye are selected from the group consisting of sclera, ciliary bodies, crystalline lens, vitreous body, and choroidea, and treating the pathology affecting the internal tissues of the eye of the subject in need thereof.

Claim 22 (Cancelled).

Claim 23 (Previously presented). The method of claim 22, wherein the pathology pathologies has a trophic, post-traumatic, infective, post-surgical,

Amendment Dated: February 6, 2007

Reply to Office Action Dated: September 6, 2006

autoimmune, dystrophic, or degenerative origin, or is originated by laser treatment.

Claim 24 (Previously presented). The method of claim 21, wherein the composition contains from 200-250  $\mu$ g/ml of nerve growth factor.

Claim 25 (Currently amended). A method for the treatment of a pathology affecting internal tissues of an eye, comprising identifying a subject in need of treatment of a pathology affecting internal tissues of an eye, topically applying the administration of a composition comprising from 200 to 500 µg/ml of nerve growth factor over an ocular surface of the a subject in need thereof, wherein said nerve growth factor passes through external tissues of said eye to said internal tissues, and treating the pathology affecting the internal tissues of the eye of the subject in need thereof.

Claim 26 (Previously presented). The method of claim 25, wherein the composition comprises the nerve growth factor in a pharmaceutically acceptable ophthalmic carrier and is in a form selected from the group consisting of solutions, suspensions, ointments, gels, or creams.

Claim 27 (Previously presented). The method of claim 25, wherein the composition is in a form selected from the group consisting of an ocular erodible insert, a polymeric membrane reservoir system to be placed in the conjunctival sac, or in combination with a local bandage and a therapeutic contact lens.

Claim 28 (Previously presented). The method of claim 25, wherein the pathology affecting the internal tissues of an eye is selected from pathologies

Amendment Dated: February 6, 2007

Reply to Office Action Dated: September 6, 2006

affecting the sclera, ciliary bodies, crystalline lens, retina, optic nerve, vitreous body, and choroidea.

Claim 29 (Previously presented). The method of claim 28, wherein the pathology has a trophic, post-traumatic, infective, post-surgical, autoimmune, dystrophic, or degenerative origin, or is originated by laser treatment.

Claim 30 (Previously presented). The method of claim 26, wherein the composition is in the form of an ophthalmic solution.

Claim 31 (Previously presented). The method of claim 30, wherein the ophthalmic solution contains from 200 to 250  $\mu$ g/ml of nerve growth factor.

Claim 32 (Previously presented). The method according to claim 25, wherein the nerve growth factor is of murine or human origin, or is a human recombinant nerve growth factor.

Claim 33 (Previously presented). The method of claim 25, wherein the pathology affecting the internal tissues of an eye is a pathology affecting the optic nerve.

Claim 34 (Previously presented). The method of claim 25, wherein the pathology affecting the internal tissues of an eye is a pathology affecting the retina.

Claim 35 (Previously presented). The method according to claim 33 wherein the ophthalmic solution contains from 200 to 250  $\mu$ g/ml of nerve growth factor.

Amendment Dated: February 6, 2007 Reply to Office Action Dated: September 6, 2006

Claim 36 (Previously presented). The method according to claim 34 wherein the ophthalmic solution contains from 200 to 250 μg/ml of nerve growth factor.